Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 683 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Oropharyngeal Clear all

Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Nasal Cavity and Paranasal Sinus Carcinoma, Oral Cavity Carcinoma, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Hypopharyngeal Carcinoma, Recurrent Laryngeal Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Carcinoma, Recurrent Oral Cavity Carcinoma, Recurrent Oropharyngeal Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVC Hypopharyngeal Carcinoma AJCC v8, Stage IVC Laryngeal Cancer AJCC v8, Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions: Celecoxib, Placebo, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Carcinoma of Unknown Primary, Head and Neck Cancer, Non-melanomatous Skin Cancer
Interventions: semaxanib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: New York, New York

Conditions: Head and Neck Cancer
Interventions: temoporfin; Drug
Lead sponsor: Quintiles, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 7
States / cities: Little Rock, Arkansas • Tampa, Florida • Evanston, Illinois + 4 more

Conditions: Head and Neck Cancer
Interventions: bortezomib, docetaxel, laboratory biomarker analysis, pharmacological study; Drug · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 7
States / cities: Hopkinsville, Kentucky • Paducah, Kentucky • Crossville, Tennessee + 3 more

Conditions: Cervical Intraepithelial Neoplasia, Cervical Neoplasms, Oropharyngeal Neoplasms, Squamous Intraepithelial Lesions of the Cervix, Hematologic Malignacies
Interventions: GeneTherapy; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2050
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Squamous Cell Carcinoma of the Oropharynx, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions: 44 doses of radiation, 54 doses of radiation; Radiation
Lead sponsor: Indiana University; Other
Eligibility: Not listed
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Carmel, Indiana • Indianapolis, Indiana

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: Cisplatin, Stereotactic Body Radiation Therapy (SBRT); Drug · Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage I Squamous Cell Carcinoma of the Oropharynx, Stage I Verrucous Carcinoma of the Oral Cavity, Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage II Squamous Cell Carcinoma of the Oropharynx, Stage II Verrucous Carcinoma of the Oral Cavity, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
Interventions: BRB Lozenge, Survey Administration, Laboratory Biomarker Analysis, pharmacological study; Dietary Supplement · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Head and Neck Cancer
Interventions: paclitaxel, semaxanib; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Caregiver Burden, Alzheimer Disease, Dementia, Oropharyngeal Dysphagia
Interventions: WeCareToFeedDysphagia web tool; Behavioral
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head and Neck
Interventions: Mitomycin-C, Pegfilgrastim; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
Interventions: Intensity Modulated Radiotherapy (IMRT), Cisplatin (or alternative), Assessment for surgical evaluation; Radiation · Drug · Procedure
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 5
States / cities: Gainesville, Florida • Chapel Hill, North Carolina • Hendersonville, North Carolina + 2 more

Conditions: Dysplasia, Carcinoma of the Oral Cavity, Carcinoma of the Oropharynx
Interventions: HPPH; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Very Low Birth Weight Infants
Interventions: application of mother's own colostrum, application of sterile water; Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: Up to 3 Days
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: HIV Infections
Interventions: miconazole Lauriad, Clotrimazole; Drug
Lead sponsor: Valerio Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 578 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 21
States / cities: Birmingham, Alabama • Los Angeles, California • Oakland, California + 17 more

Conditions: Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma
Interventions: Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, External Beam Radiation Therapy, Paclitaxel, Positron Emission Tomography, Questionnaire Administration; Procedure · Drug · Radiation + 1 more
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Head and Neck Cancer
Interventions: metal patch tests; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2009
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Aspiration
Interventions: Sidelying, Upright; Other
Lead sponsor: Connecticut Children's Medical Center; Other
Eligibility: 38 Weeks to 56 Weeks
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Squamous Cell Carcinoma of the Oropharynx, HPV
Interventions: Cetuximab, Radiotherapy; Drug · Radiation
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Head and Neck Cancer, Melanoma, HPV-Related Malignancy, HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Lung Cancer, Nonsmall Cell, Melanoma (Skin)
Interventions: Tumor Profiling; Diagnostic Test
Lead sponsor: Repertoire Immune Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Scottsdale, Arizona • Ann Arbor, Michigan • Nashville, Tennessee

Conditions: Head and Neck Cancer, Infection, Oral Complications
Interventions: fluconazole, radiation therapy; Drug · Radiation
Lead sponsor: University of Miami; Other
Eligibility: 21 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2006
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Oropharyngeal Dysphagia
Interventions: Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR); Drug
Lead sponsor: Peter Belafsky, MD; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Head and Neck Cancer
Interventions: carboplatin, cisplatin, docetaxel, fluorouracil; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 14
States / cities: La Jolla, California • Denver, Colorado • Boca Raton, Florida + 11 more

Conditions: Oropharynx Cancer
Interventions: Gabapentin, Placebo Oral Capsule; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Search by objective public record fields.

Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer

SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck

Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy

Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies

Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell Carcinoma

Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck

Freeze-Dried Black Raspberries in Preventing Oral Cancer Recurrence in High At-Risk Appalachian Patients Oral Cancer Survivors

SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck

Reducing Burden in Care Partners of Community-Dwelling Persons With Dementia and Oropharyngeal Dysphagia

Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies

De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study

A Trial of Photodynamic Therapy With HPPH for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx

Oropharyngeal Colostrum for Immune Stimulation in Very Low Birth Weight Infants

Efficacy and Safety Study of Miconazole Lauriad to Treat Oropharyngeal Candidiasis in HIV Patients

Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer

Contact Allergies to Dental Metal as a Possible Risk Factor for Oral Cancer

The Effect of Body Position on Oropharyngeal Swallow Function in Infants

Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients

This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.

Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer

Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia

Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)

Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Cancer